Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
While conventional oncology considers all forms of pre-Myeloma to be “asymptomatic” as the studies linked and excerpted below explain, many MGUS patients experience symptoms such as bone pain, nerve pain and fractures.
MGUS at a glance-
My name is David Emerson. I am a long-term myeloma survivor and multiple myeloma cancer coach. I am writing about MGUS for two main reasons. First, because people who are diagnosed with MGUS are often told to “watch and wait.” And second, 22 plus years surviving multiple myeloma has taught me that there are many evidence-based, non-toxic therapies that MGUS/SMM/MM patients can pursue on their own.
To learn more about how to alleviate bone pain, along with other evidence-based therapies that can help you prevent the development of a Multiple Myeloma diagnosis, please watch the short video below:
Have you been diagnosed with MGUS or some other form of pre-MM? Are you experiencing bone pain? Scroll down the page, post a comment or a question and I will reply to you ASAP.
Consider MGUS Therapies such as:
“There was a 2.7-fold increase in the risk of axial fractures but no increase in limb fractures…
Altogether, 200 patients experienced 385 fractures. Compared with expected rates in the community, statistically significant increases were seen for fractures at most axial sites, for example, vertebrae…
In a multivariate analysis, the independent predictors of any subsequent fracture were
Baseline monoclonal protein level, a determinant of myeloma progression, did not predict fracture risk.
“In this issue of Blood, Farr et al showed that patients with monoclonal gammopathy of undetermined significance (MGUS) have increased cortical bone porosity and reduced bone strength,1 conditions that can lead to the increased fracture risk, which has been reported in MGUS patients…
The International Myeloma Working Group (IMWG) also suggests bisphosphonates in all MGUS patients with proven osteopenia or osteoporosis.9 Indeed, bisphosphonates increase bone strength through decreasing bone turnover…”
“While individuals with MGUS had normal bone-mineral density (BMD), their bone volume was increased compared to patients without MGUS. In addition, men with MGUS had an almost 50% increased risk of fractures, compared with other men. “Our findings suggest an effect of MGUS on bone metabolism that does not affect BMD,” the authors wrote of the findings.
In this cohort study, the researchers screened for MGUS in more than 5,000 older Icelandic participants included in the Age, Gene/Environment Susceptibility–Reykjavik Study (AGES-RS), and measured bone metabolism (BMD and bone volume), as well as subsequent fracture risk, over a median of 6.9 years of follow-up (range = 0-11.3 years). BMD and bone geometry were evaluated using quantitative computerized tomography (QCT) in the lumbar spine and the left hip with a four-row detector CT system…
During follow-up, 1,334 fractures were recorded: 74 in the MGUS group (34 in men and 40 in women) and 62 in the LC-MGUS group (19 in men and 43 in women). The risk of fracture was not significantly increased in those with MGUS or LC-MGUS, compared with other AGES-RS participants, but was increased for men with MGUS, compared with other men (hazard ratio [HR] = 1.49; 95% CI 1.03-2.08).
The researchers again noted an unexpected finding: Women with and without MGUS had similar risks of bone fracture (HR=1.02; 95% CI 0.74-1.40). “This suggests an effect of MGUS on bone metabolism in men that is not noted in women, possibly as a result of other stronger risk factors in postmenopausal women,” they wrote, explaining that the generally enhanced rate of bone loss in women with osteoporosis “may mask the effect of MGUS on bone metabolism.”
Eighteen patients with MGUS progressed to MM during follow-up, four of whom had a fracture before progression (2 men and 2 women). In addition, patients with MGUS who developed fractures had a decreased BMD at the spine (p<0.001), femoral neck (p=0.005), trochanter (p<0.001), and total hip (p<0.001), compared with others with MGUS, “indicating that processes known from osteoporosis play a role in fractures in this group, just like in the general population,” the researchers noted.
Overall, though, the risk of fractures had no significant association with the risk of progression to MM, compared with patients with MGUS without fractures (HR=0.77; 95% CI 0.24-2.47).
“Our results do not support measuring BMD in [patients with] MGUS to screen for osteopenia/osteoporosis, as our study shows that they do not have a lower BMD than others in the same age group,” the authors concluded. “Studies are needed to determine how patients with MGUS with increased risk of fractures can be identified and how and if they should be treated prophylactically…”